Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
Short/dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant for telomere maintenance genes. However, it remains unknown whether physiological aging leads to short telomeres in the lung, thus leading to IPF with aging. Here, we find that physiological aging in wild-type mice leads to telomere shortening and a reduced proliferative potential of alveolar type II cells and club cells, increased cellular senescence and DNA damage, increased fibroblast activation and collagen deposits, and impaired lung biophysics, suggestive of a fibrosis-like pathology. Treatment of both wild-type and telomerase-deficient mice with telomerase gene therapy prevented the onset of lung profibrotic pathologies. These findings suggest that short telomeres associated with physiological aging are at the origin of IPF and that a potential treatment for IPF based on telomerase activation would be of interest not only for patients with telomerase mutations but also for sporadic cases of IPF associated with physiological aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Telomerase deficiency and natural aging in the mouse lung leads to telomere shortening and reduction in the number of ATII and club cells. (A and B) Generation of Tert+/+ and G3 Tert−/− mice and scheme of lung tissue harvesting. (A) Heterozygous Tert+/− mice were crossed to obtain Tert+/+ and G1 Tert−/− mice, and successive crosses between G1 Tert−/− and then G2 Tert−/− mice were made to generate G3 Tert−/− mice. (B) Scheme of sacrifice and collection of lungs from Tert+/+ and G3 Tert−/− mice at different time points. (C) Representative images showing a Q-FISH for telomere spot fluorescence in ATII and club cells (Cy3Tel probe [red], SFTPC- and SCGB1A1-positive cells [green]) and nuclei stained with DAPI (blue; left and center right), SFTPC (brown, red arrowheads; center left), and SCGB1A1 (brown, green arrowheads; right) immunostainings in lung sections from Tert+/+ and G3 Tert−/− at different time points. (D–I) Quantification of mean telomere fluorescence (mean spot intensity; D and F), percentage of short telomeres in ATII and club cells corresponding to the 20th percentile of the fluorescence intensity values of controls (5-wk-old Tert+/+ mice; E and G), and SFTPC-positive ATII cells (%) and SCGB1A1-positive club cells per epithelium length (millimeters; H and I). Quantifications were performed on five different alveolar areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.](https://figures.cochat.ai/paper-figures/7291dc599f4d484faf0785adf7b35579/telomerase-treatment-prevents-lung-profibrotic-pathologies-associated-with-figure-1.jpg)



![Figure 5. Physiological aging leads to impaired surfactant activity which is partially restored by telomerase gene therapy in both wild-type mice and telomerase-deficient mice. (A and B) Captive bubble results from Tert+/+ and G3 Tert−/− mice with increasing weeks of age. (C and D) Captive bubble results from 71–72-wk-old Tert+/+ and G3 Tert−/− mice treated with AAV9-empty or AAV9-Tert. (A and C) Top: Surface tension obtained 1 s after applying surfactant onto the air bubble (initial adsorption). Bottom: Surface tension obtained 1 s after the bubble expansion (postexpansion [PE] adsorption). (B and D) Top: Representative γ-relative area isotherms obtained under breathing-like dynamic cycles for each group tested. Bottom: Minimum and maximum γ along with the relative area of compression obtained during the 20th cycle. White bars represent Tert+/+ mice. Gray bars represent G3 Tert−/− mice. Data are expressed as mean ± SEM (n = 5–6 animals per group). *, P < 0.05; **, P < 0.01. Between different ages for each condition: One-way ANOVA with post hoc Dunn–Sidak multiple comparison test. Between different conditions within the same age: following a Shapiro–Wilk normality test, two-sample unpaired t test, or Mann–Whitney test when appropriate. γ, surface tension; max, maximum; min, minimum.](https://figures.cochat.ai/paper-figures/83a7bf0506ee43e09cb6b02a43e86288/telomerase-treatment-prevents-lung-profibrotic-pathologies-associated-with-figure-5.jpg)

![Figure 6. Telomerase gene therapy in the mouse lung results in telomere elongation and increased number of ATII and club cells. (A) Experimental protocol for the administration of AAV9-Tert and AAV9-empty virus. 27–30-wk-old Tert+/+ and G3 Tert−/− mice were administered with 2E12vg of AAV9-Tert and AAV9-empty virus by intravenous tail injection. Animals were sacrificed 21 wk later for lung tissue harvesting. (B) Total lung mRNA levels of Tert normalized to 18S expression in AAV9-empty– and AAV9-Tert–treated animals. (C–H) Quantification of mean telomere fluorescence (mean spot intensity; C and E), percentage of short telomeres in ATII and club cells corresponding to the 20th percentile of the fluorescence intensity values of controls (5-wk-old Tert+/+ mice; D and F), and SFTPC-positive ATII cells (%) and SCGB1A1-positive club cells per epithelium length (millimeters) in AAV9-Tert– and AAV9-empty–treated mice (G and H). (I) Representative images showing a Q-FISH for telomere spot fluorescence in ATII and club cells (Cy3Tel probe [red], SFTPC- and SCGB1A1-positive cells [green], and nuclei stained with DAPI [blue]; left and center right), and SFTPC (brown, red arrowheads; center left) and SCGB1A1 (brown, green arrowheads; right) immunostainings in lung sections from Tert+/+ and G3 Tert−/− mice treated with the AAV9-Tert (upper panels) or AAV9-empty (lower panels) virus. (J–L) Changes in total lung mRNA expression levels of the surfactant markers Sftpa1, Sftpc, and Sftpd normalized to 18S expression. Quantifications were performed on five different alveolar areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.](https://figures.cochat.ai/paper-figures/cc6fac0ba4b4469c8190b9aaa0069ff7/telomerase-treatment-prevents-lung-profibrotic-pathologies-associated-with-figure-6.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, expression of telomerase using adeno-associated vectors (AAVs) in alveolar epithelial type II cells led to TAF reduction, decreased inflammation and improved lung function in telomerase-mutant and wild-type aged mice63,64.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In various murine liver injury models, stellate cells can acquire senescence markers, including p21, p16, and SA-β-gal, and express certain SASP factors80–83.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Self-citationRaghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“In mammals, telomeric DNA consists of TTAGGG repeats bound by a six-protein complex termed “shelterin” (Liu et al., 2004; de Lange, 2005).”
BackgroundAging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1×
“Previous authors have also suggested a role for senescence in IPF (Selman and Pardo, 2014; Spagnolo et al., 2015; Pardo and Selman, 2017; Campisi, 2013).”
BackgroundA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108 · cited 1×
“To this end, we performed a full characterization of mouse lungs at different ages (5, 8–9, 42–49, and 92–125 wk of age) in both wild-type and third-generation (G3) telomerase-deficient mice with short telomeres (Blasco et al., 1997) as a control for lung pathologies associated with accelerated telomere shortening (Fi…”
MethodSelf-citationSwitching and Signaling at the Telomere
Blackburn, E. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00492-5 · Cited by 2,107 · cited 1×
“Telomeres are protective structures at the ends of eukaryotic chromosomes that are essential for chromosome stability (Blackburn, 2001).”
Research works printed but not linked: 1
- Pardo, 2017, Fibroblast Senescence and Apoptosis, Ajrcmb, 56, 145
Cited by
Telomere dysfunction in ageing and age-related diseases
Rossiello, F., Jurk, D., Passos, J. F., & d’Adda di Fagagna, F. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00842-x · Cited by 754
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Guidelines for minimal information on cellular senescence experimentation in vivo
Ogrodnik, M., Carlos Acosta, J., Adams, P. D., d’Adda di Fagagna, F., Baker, D. J., Bishop, C. L., Chandra, T., Collado, M., Gil, J., Gorgoulis, V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.059 · Cited by 376
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Pardo, A., & Selman, M. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0373ps · Cited by 117
Metadata
- Authors
- Piñeiro-Hermida, S., Autilio, C., Martínez, P., Bosch, F., Pérez-Gil, J., & Blasco, M. A.
- Affiliations
- Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre, Madrid, Spain 1
- Universidad Complutense de Madrid (ES)
- Spanish National Cancer Research Centre (ES)
- Universitat Autònoma de Barcelona (ES)
- Department of Biochemistry and Molecular Biology, Research Institute “Hospital 12 de Octubre (imas12),” Complutense University, Madrid, Spain 2
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2020-08-10
- Volume
- 219
- Issue
- 10
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC7659728
- OpenAlex
- W3048397235
- Cited by
- 60
- References
- 99
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 12 · 2020: 3
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Cell Biology (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Library Open Repository (Universidad Complutense Madrid) (submittedVersion, cc-by-nc-sa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- RIUR (Universidad de La Rioja) (submittedVersion, other-oa)
- Funders
- Spanish Ministry of Economy and Competitiveness (SAF2013-45111-R, SAF2015-72455-EXP)
- Comunidad de Madrid Project (S2017/BMD-3770)
- World Cancer Research Fund (16-1177)
- Spanish Ministry of Science and Innovation (RTI2018-094564-B-100, DTS17/ 00152, SAF2017-82623-R)
- Regional Government of Madrid (P2018/NMT-4389)
- Fundación Botín
- Fundación Banco Santander
- Instituto de Salud Carlos III
- European Regional Development Fund
- Spanish Estate Research Agency
- RyPSE-CM (B2017/BMD-3770)
- Community of Madrid
- European Social Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- telomerase, idiopathic pulmonary fibrosis, physiological aging, telomere shortening, pulmonary fibrosis, cellular senescence, alveolar type II cells, Clara cells, fibroblast activation, collagen deposition, DNA damage
- MeSH terms
- Aging, Animals, Bleomycin, Disease Models, Animal, DNA Damage, Humans, Lung, Telomere, Cellular Senescence, Mice, Knockout, Telomerase, Mice, Idiopathic Pulmonary Fibrosis, Telomere Shortening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging. https://app.cochat.ai/papers/10.1083/jcb.202002120
- The paper
- Piñeiro-Hermida, S., Autilio, C., Martínez, P., Bosch, F., Pérez-Gil, J., & Blasco, M. A. (2020). Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging. Journal of Cell Biology. https://doi.org/10.1083/jcb.202002120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.